Adjuvant therapy for resectable pancreatic adenocarcinoma: Review of the current treatment approaches and future directions

Antoniou, Georgios; Kountourakis, Panteleimon; Papadimitriou, Κonstantina; Vassiliou, V.; Papamichael, Demetris

doi:10.1016/j.ctrv.2013.05.008

Cited by 31 publications

(23 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is the fourth leading cause of death by cancer in the world, and its 5-year relative survival is currently 8% 1,2. The high mortality rate is caused by its aggressive biological properties, late symptom onset, and lack of specific treatments 3,4. Therefore, it is necessary to learn more about PC at the molecular level and identify a new potential therapeutic target for anticancer drugs.…”

Section: Introductionmentioning

confidence: 99%

Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells

Ye¹,

Su²,

Huang³

et al. 2016

OTT

View full text Add to dashboard Cite

Isoorientin (or homoorientin) is a flavone, which is a chemical flavonoid-like compound, and a 6-C-glucoside of luteolin. Isoorientin has been demonstrated to have anti-cancer activities against various tumors, but its effects on pancreatic cancer (PC) have not been studied in detail. In this study, we aim to investigate whether isoorientin has potential anti-PC effects and its underlying mechanism. In PC, isoorientin strongly inhibited the survival of the cells, induced cell apoptosis, and decreased its malignancy by reversing the expression of epithelial–mesenchymal transition and matrix metalloproteinase and decreased vascular endothelial growth factor expression. Meanwhile, we investigated the activity of the AMP-activated protein kinase (AMPK) signaling pathway after isoorientin treatment, which was forcefully activated by isoorientin, as expected. In addition, in the PC cells that were transfected with lentivirus to interfere with the expression of the gene PRKAA1, there were no differences in the apoptosis rate and the expression of malignancy biomarkers in the tumors of the isoorientin-treated and untreated groups. Thus, we demonstrated that isoorientin has potential antitumor effects via the AMPK signaling pathway, and isoorientin merits further investigation.

show abstract

Section: Introductionmentioning

confidence: 99%

Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells

Ye¹,

Su²,

Huang³

et al. 2016

OTT

View full text Add to dashboard Cite

show abstract

“…Historically, chemotherapy (CTX) was one of the standard treatments for GI cancers (2)(3)(4)(5)(6)(7)(8). These agents are administered to reduce tumor burden, decrease tumor-related symptoms, improve patients' well-being, and prolong survival (9)(10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy

Tantoy

Dhruva

Cataldo

et al. 2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Background: Approximately 28% of patients with gastrointestinal (GI) cancers will receive targeted therapy (TT) because of the associated increases in survival. Only four studies have examined the symptom experience of these patients. To date, no studies have evaluated for differences in symptom occurrence, severity, and distress between patients who received chemotherapy (CTX) alone (n=304) or CTX with TT (n=93).Methods: Patients completed self-report questionnaires, approximately one week after they received CTX.A modified version of the Memorial Symptom Assessment Scale (MSAS) was used to obtain data on symptom occurrence, severity, and distress. Binary logistic regression analyses were used to test for differences in symptom occurrence rates between the two treatment groups. Ordinal logistic regression analyses were used to test for differences in severity and distress ratings between the two treatment groups.Results: Patients who received CTX with TT were significantly younger (P=0.009); were diagnosed with cancer longer (P=0.004); had a higher number of prior treatments (P=0.024); had metastatic disease, specifically to the liver (P<0.001); had a diagnosis of anal, colon, rectum, or colorectal cancer (CRC) (P<0.001); and were positive for detection of B-Raf proto-oncogene, serine/threonine kinase (BRAF) and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations (both P<0.001). In addition, CTX treatment regimens were significantly different between the two groups (P<0.001). After controlling for significant covariates, patients who received TT reported lower occurrence rates for lack of energy, cough, feeling drowsy, and difficulty sleeping (all, P<0.05). Patients who received TT reported lower severity scores for dry mouth (P=0.034) and change in the way food tastes (P=0.035). However, they reported higher severity scores for "I don't look like myself" (P=0.026).No differences in symptom distress scores were found between the two treatment groups.Conclusions: This study is the first to evaluate for differences in the symptom experience of GI cancer patients who received CTX alone or CTX with TT using a multidimensional symptom assessment scale.While between group differences in patients' symptom experiences were identified, both treatment groups warrant ongoing assessments to optimally manage their symptoms.

show abstract

“…For oesophageal cancer, complete response to neoadjuvant chemoradiation varies between 15% and 40% [3]. Studies investigating the efficacy of (radio)chemotherapy in patients with pancreatic ductal adenocarcinoma generally show an overall limited gain in median survival [4][5][6]. Oesophageal carcinomas have been associated with reduced oxygenation and resulting hypoxia related gene-expression [7].…”

Section: Introductionmentioning

confidence: 99%

Feasibility and repeatability of PET with the hypoxia tracer [18F]HX4 in oesophageal and pancreatic cancer

Klaassen

Bennink

Tienhoven

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

Adjuvant therapy for resectable pancreatic adenocarcinoma: Review of the current treatment approaches and future directions

Cited by 31 publications

References 74 publications

Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells

Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells

Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy

Feasibility and repeatability of PET with the hypoxia tracer [18F]HX4 in oesophageal and pancreatic cancer

Contact Info

Product

Resources

About